This website is intended for healthcare professionals
Respiratory Handbook

The professional's guide to product selection

Daxas - Roflumilast - AstraZeneca UK Ltd

AstraZeneca

Description

Roflumilast is a phosphodiesterase type-4 inhibitor with anti-inflammatory properties.

• Adult: 250 mcg once daily for 28 days, then 500 mcg once daily for maintenance.

Indications

Use in conjunction with bronchodilators for the maintenance of patients with COPD associated with chronic bronchitis.

Contraindications

The manufacturer suggests avoiding if there is any hepatic impairment present, pregnancy or breast feeding.

Preparations Available

Tablets

Sizes Available

Tablets
250 mcg, 28 tablets 
500 mcg, 30 tablets 

More on: Xanthines , Roflumilast